분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-03-08 15:43:18 , Hit : 1687
 Merck hepatitis C drugs work in HIV co-infected patients -study

March 5  Wed Mar 5, 2014 5:56pm EST

0 Comments

(Reuters) - A combination of oral drugs for hepatitis C developed by Merck & Co appeared to be well tolerated and highly effective in treating the liver disease in patients also infected with HIV, according to data from a midstage clinical trial presented on Wednesday.

The Merck drugs, MK-5172 and MK-8742, which belong to promising new classes of anti-viral medicines, were tested over a 12-week course of treatment both with and without the older hepatitis C drug ribavirin in co-infected patients.

After 12 weeks of treatment, all 29 patients who received the two Merck drugs and ribavirin had undetectable levels of the hepatitis C virus. Among those who got just the experimental Merck drugs, 26 of 29, or 90 percent, appeared to have the hepatitis C virus eliminated from their blood.

If the virus remains undetectable 12 weeks after completion of treatment, those patients are considered cured.

The available data from the ongoing study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. More detailed results of the study dubbed C-Worthy are expected to be presented at a European medical meeting in April, Merck said.

No co-infected patients discontinued treatment due to either an adverse side effect or study medication intolerance, Merck said. The most common side effects of fatigue and headache were no more prevalent in patients with hepatitis C and HIV infection than what had been observed in patients with hepatitis C alone.

A new era in treatment for the serious liver disease has begun with several companies, including Gilead Sciences Inc , AbbVie and Bristol-Myers Squibb Co, developing all oral treatment regimens that have demonstrated cure rates well in excess of 90 percent with treatment durations of just 12 weeks or shorter.

Current standard treatments take 24 to 48 weeks and include the injected drug interferon that causes miserable flu-like symptoms and cure about 75 percent of patients.

Those also living with the virus that causes AIDS are an important patient population.

About seven million people worldwide are co-infected with HIV and hepatitis C (HCV). Co-infected patients have a three times higher rate of progression to cirrhosis and a six times higher risk of liver decompression than those with HCV alone.







927   바이러스를 저지시키는 방법  이성욱 2014/08/15 1650
926   금발은 어떻게 생겨날까? - DNA 글자 하나가 머리칼의 색깔을 바꾼다.  이성욱 2014/06/05 1651
925   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1655
924   DNA가 비슷한 배우자를 선택하는 경향  이성욱 2014/05/23 1656
923   Pfizer Abandons AstraZeneca Takeover Bid  이성욱 2014/05/29 1656
922   STAP 논문, 결국 62일 만에...  이성욱 2014/04/02 1659
921   유전자요법을 이용한 신경근육접합부 결함 치료  이성욱 2014/09/24 1664
920   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1664
919   US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1665
918   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1666
917   존재하지 않았던 STAP 줄기세포  이성욱 2014/06/05 1667
916   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1668
915   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1669
914   야심찬 브레인 프로젝트  이성욱 2014/06/11 1680
913   박테리아와 바이러스에 존재하는 나노 바이오모터(biomotor)  이성욱 2014/07/18 1681
912   치료가 어려운 C형 간염에 대한 새로운 경구 병용 요법  이성욱 2014/08/01 1682
  Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1687
910   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1687
909   Targeting DNA  이성욱 2012/06/07 1698
908   전령 RNA에서의 슈도유리딜화  이성욱 2014/09/19 1698

[이전 10개] [1]..[11][12][13][14][15][16][17] 18 [19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN